






Abacavir + lamivudine + lopinavir + ritonavir

REJECTED

The Expert Committee, after evaluation, declines to list the medicine proposed in the application.
The Model List of Essential Medicines reports reasons that Committee Members have identified for denying listing.

General description

INN	Abacavir + lamivudine + lopinavir + ritonavir
Medicine type	Chemical agent
EML status history	Application rejected in 2021 (TRS 1035) for Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
Wikipedia	Abacavir + lamivudine + lopinavir + ritonavir 
DrugBank	Abacavir  , Lamivudine  , Lopinavir  , Ritonavir 

Recommendations

Section Fixed-dose combinations of antiretrovirals

Oral > Solid: 30 mg + 15 mg + 40 mg + 10 mg capsule containing oral granules

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

